Halozyme Therapeutics, Inc. (NASDAQ:HALO) Stock Has Consensus Price Target of $99.55

Halozyme Therapeutics, Inc. (NASDAQ:HALO) has earned an average recommendation of “Moderate Buy” from the thirteen research firms that are presently covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has issued a strong buy rating on the company. The average 1 year price objective among analysts that have issued a report on the stock in the last year is $99.55.

A number of analysts have recently commented on HALO shares. TD Cowen boosted their price objective on Halozyme Therapeutics from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Tuesday, October 13th. Stifel Nicolaus set a $130.00 price objective on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Wall Street Zen upgraded shares of Halozyme Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 8th. JPMorgan Chase & Co. boosted their target price on Halozyme Therapeutics from $70.00 to $78.00 and gave the stock a “neutral” rating in a report on Thursday, October 8th. Finally, Weiss Ratings upgraded Halozyme Therapeutics from a “buy (b-)” rating to a “buy (b)” rating in a research note on Monday, August 31st.

Insider Buying and Selling at Halozyme Therapeutics

In other Halozyme Therapeutics news, Director Matthew Posard sold 5,230 shares of the firm’s stock in a transaction on Thursday, October 1st. The shares were sold at an average price of $108.54, for a total value of $567,664.20. Following the sale, the director directly owned 53,609 shares in the company, valued at $5,818,720.86. This trade represents a 8.89% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the business’s stock in a transaction dated Thursday, October 8th. The stock was sold at an average price of $109.40, for a total transaction of $2,188,000.00. Following the transaction, the chief executive officer owned 767,780 shares in the company, valued at approximately $83,995,132. The trade was a 2.54% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 125,852 shares of company stock valued at $13,538,046 in the last ninety days. Company insiders own 2.50% of the company’s stock.

Hedge Funds Weigh In On Halozyme Therapeutics

Hedge funds have recently modified their holdings of the stock. Bank of America Corp DE bought a new position in Halozyme Therapeutics in the 2nd quarter valued at $214,504,000. William Blair Investment Management LLC acquired a new stake in Halozyme Therapeutics in the second quarter worth $196,540,000. Congress Asset Management Co. lifted its holdings in Halozyme Therapeutics by 85.6% during the third quarter. Congress Asset Management Co. now owns 2,281,615 shares of the biopharmaceutical company’s stock worth $251,890,000 after acquiring an additional 1,052,509 shares in the last quarter. Royal London Asset Management Ltd. lifted its holdings in shares of Halozyme Therapeutics by 12.4% during the 2nd quarter. Royal London Asset Management Ltd. now owns 1,810,815 shares of the biopharmaceutical company’s stock valued at $141,732,000 after purchasing an additional 200,262 shares in the last quarter. Finally, First Trust Advisors LP boosted its holdings in shares of Halozyme Therapeutics by 46.5% in the first quarter. First Trust Advisors LP now owns 1,482,340 shares of the biopharmaceutical company’s stock valued at $95,804,000 after buying an additional 470,558 shares during the period. 97.79% of the stock is owned by institutional investors and hedge funds.

Halozyme Therapeutics Trading Up 0.9%

Shares of HALO opened at $131.18 on Friday. The company has a debt-to-equity ratio of 13.50, a current ratio of 2.71 and a quick ratio of 2.31. The stock has a market cap of $14.89 billion, a price-to-earnings ratio of 26.38, a price-to-earnings-growth ratio of 0.49 and a beta of 0.88. Halozyme Therapeutics has a 1-year low of $61.22 and a 1-year high of $132.55. The firm has a 50 day simple moving average of $113.21 and a 200-day simple moving average of $83.16.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings results on Thursday, August 6th. The biopharmaceutical company reported $2.28 EPS for the quarter, beating the consensus estimate of $1.79 by $0.49. The company had revenue of $481.00 million during the quarter, compared to analysts’ expectations of $402.28 million. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The firm’s revenue was up 47.7% on a year-over-year basis. During the same quarter in the previous year, the business earned $1.54 EPS. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Equities analysts forecast that Halozyme Therapeutics will post 8.31 EPS for the current fiscal year.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.